> News > Ichnos Glenmark Innovation Shares Promising Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, for Patients with Heavily Pretreated Multiple Myeloma
09.12
2024

Ichnos Glenmark Innovation Shares Promising Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, for Patients with Heavily Pretreated Multiple Myeloma

Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreated Multiple Myeloma
No dose-limiting toxicities were observed up to weekly subcutaneous doses of 1.2 mg/kg, with mostly mild Cytokine Release Syndrome, no cases of neurotoxicity, and no discontinuations due to adverse events. ISB 2001 demonstrated an ORR of 83% in heavily pretreated patients treated at active doses (0.05 mg/kg and higher)

Company related to the news